The influence of adequate drug therapy on the clinical symptoms and level of serum amyloid A in patients with chronic obstructive pulmonary disease.
DOI:
https://doi.org/10.26641/2307-0404.2018.2(part1).129513Keywords:
chronic obstructive pulmonary disease, systemic inflammation, serum amyloid AAbstract
The aim of our research was to study the dynamics of the level of SAA in COPD patients in the stable phase of the pathological process against the background of basic therapy. We studied 37 stable COPD patients with II-IV degree of ventilation violations according to the GOLD classification, distributed in two subgroups depending on the adequacy of taking basic therapy. Stable COPD patients, irrespective of the severity of the course of the disease in conditions of inadequate treatment have greater symptom severity, the number of exacerbations over the past year and the level of SAA than patients taking long-term therapy according to COPD severity. Taking therapy corresponding to the severity of the disease within three months by COPD patients helps to reduce the severity of COPD symptoms to the level of these indicators in patients taking adequate therapy for a longer period of time. Treatment of COPD patients which corresponds to the severity of the disease within three months contributes to a significant reduction of SAA level.
References
[Order of the Ministry of Health of Ukraine N 555 dated June 27, 2013 "An Approval and Implementation of Medical-Technological Documents on Standardization of Medical Assistance in the Case of Chronic Obstructive Pulmonary Disease]. Kyiv. 2013;146. Ukrainian.
Abo-Sabe S, Abo Bakr BW. Serum amyloid a in chronic obstructive pulmonary disease AsianAcademyofManagement Journal. 2008;6:27-34.
Gan WQ, Man SF, Senthilselvan A. Association between chronic obstructive pulmonary diseaseand systemic inflammation: a systematic review and a metaanalysis Thorax. 2004;59:574-80.
Global initiative for chronic obstructive lung disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. [Internet]. Update 2017;14. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2017_Jan23.pdf.
Jovanovic DB. Clinical importance of determination of serum amyloid A. Srp. Arh. Celok. Lek. 2004;132(7-8):267-71.
Paul SF, Sin D. Effects of Corticosteroids on Systemic Inflammation in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society. 2005;2:78-82.
Wouters EF, Wouters BB, Augustin IM, Franssen FM. Personalized medicine and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2017;23(3):241-6.
Smith ST, Yerkovich DJ, Towers MA, Carroll ML. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J. 2011;37:516-22.
Bozinovski S, Hutchinson A, Thompson ML. Serum amyloid A is a biomarker of acute exacerbation of COPD. Am J RespirCrit Care Med: 2007;177:269-78.
Urieli-Shoval S, Linke RP et al. Expression and function of serum amyloid A, major acute-phase protein, in normal and disease states. Curr. Opin. Hematol. 2000;7(1):64-69.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2018 Medicni perspektivi (Medical perspectives)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
